Berdazimer Topical Gel, 10.3%: First Approval
- PMID: 38409574
- DOI: 10.1007/s40265-024-02012-9
Berdazimer Topical Gel, 10.3%: First Approval
Abstract
Berdazimer topical gel, 10.3% (ZELSUVMI™) is a nitric oxide (NO) releasing topical gel developed by Novan Inc. (a Ligand Pharmaceuticals company) for the treatment of molluscum contagiosum (MC). Novan has used their proprietary NO-based technology platform (NITRICIL™), which stores gaseous NO species on large polymers, in the development of berdazimer topical gel, 10.3%. In January 2024, berdazimer topical gel, 10.3% was approved for the topical treatment of MC in adult and paediatric patients 1 year of age and older in the USA. This article summarizes the milestones in the development of berdazimer topical gel, 10.3% leading to this first approval for the treatment of MC.
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
References
-
- US Food & Drug Administration. FDA approves first treatment for molluscum contagiosum [media release]. 24 Jul 2023. https://www.fda.gov/ .
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
